PET/MR bests PET/CT in identifying prostate cancer recurrence

06/21/2013 | Medscape (free registration)

PET/MR imaging with 11C-choline for restaging of prostate cancer was well-tolerated and able to identify more small local recurrences than PET/CT, according to a study presented at the SNMMI Annual Meeting. The radiation dose exposure with PET/MR imaging is about 80% lower than with PET/CT, researchers said, suggesting the approach may be particularly beneficial for patients who need a number of tests.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA